Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA MEETING

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 18, 2024 6:22pm

75 Views

Post# 36047567

RE:RE:RE:RE:RE:RE:FDA MEETING

" .... by the end of May, before ASCO 2024."

On Thursday Matt Coffey clarified matters on the timing that the FDA Type C Meeting which was recently granted and was scheduled for 35 days after the April 11, 2024 request.

<< Previous

Bullboard Posts

Next >>

Drilling company poised to capitalize on market conditions